Korean J Urol Oncol.
2021 Feb;19(1):30-39. 10.22465/kjuo.2021.19.1.30.
The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment
- Affiliations
-
- 1Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea
- KMID: 2513365
- DOI: http://doi.org/10.22465/kjuo.2021.19.1.30
Abstract
- Urothelial cancer is the seventh most common cancer among men worldwide. Bacille de Calmette-Guérin is a type of anticancer immunotherapy that has been used to treat targeted bladder cancer, but the number of patients with treatment-refractory advanced urothelial cancer, patients has been increasing recently. To overcome this, enfortumab vedotin (novel nectin-4 targeting antibody-drug conjugate) known as antibody-drug conjugate (ADC), was approved. We describe the clinical development process of ADC and the potential for future development as a bladder cancer treatment.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
- Review of Antibody-Drug Conjugates
- A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
- Antibody-Drug Conjugates in Head and Neck Cancer
- Chemotherapy in Advanced Urothelial Carcinoma
